Zavegepant hydrochloride is under clinical development by Pfizer and currently in Pre-Registration for Migraine. According to GlobalData, Pre-Registration drugs for Migraine have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Zavegepant hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zavegepant hydrochloride overview
Vazegepant is under development for the treatment of allergic asthma, prevention of migraine, pulmonary complications of COVID-19 disease and an unspecified indication. It is administered by intranasal in the form of spray, intravenous and oral route. The drug candidate is a new chemical entity (NCE) which acts by targeting Calcitonin Gene-Related Peptide Type 1 Receptor (CGRP).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Zavegepant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.